Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831

Abstract

Background: Data suggest that weight, and specifically body mass index (BMI), plays a role in breast cancer development and outcome. The authors hypothesized that there would be a correlation between BMI and clinical outcome in patients with early stage, human epidermal receptor 2 (HER2)-positive breast cancer enrolled in the N9831 adjuvant trial.

Methods: Patients were grouped according to baseline BMI as follows: normal (BMI <25 kg/m(2)), overweight (BMI ≥25 kg/m(2) and <30 kg/m(2)), and obese (BMI ≥30 kg/m(2)). Disease-free survival (DFS) was estimated using the Kaplan-Meier method. Comparisons between treatment arms A, B, and C (chemotherapy with or without trastuzumab) were performed using a stratified Cox proportional hazards model.

Results: Analysis was completed on 3017 eligible patients. Obese patients were more likely to be older and postmenopausal (P < .0001 for both), to have larger tumors (P = .002), and to have positive lymph nodes (P = .004). In the pooled analysis cohort, differences in DFS among the BMI groups were statistically significant (5-year DFS rate: 82.5%, 78.6%, and 78.5% for normal weight, overweight, and obese women, respectively; log-rank P = .02). The adjusted hazard ratio comparing the DFS of overweight women with the DFS of normal women was 1.30 (95% confidence interval, 1.06-1.61); and, comparing the DFS of obese women with the DFS normal women, the adjusted hazard ratio was 1.31 (95% confidence interval, 1.07-1.59). There were no statistically significant differences in DFS by weight group for women within any trial arm.

Conclusions: Patients with early stage, HER2-positive breast cancer and normal BMI had a better 5-year DFS compared with overweight and obese women. The current results indicated that adjuvant trastuzumab improves clinical outcome regardless of BMI.

Figure 1

Disease-free survival by BMI group for patients pooled across treatment arms

Figure 2

Figure 2a: Disease-free survival BMI group for treatment Arm A: No trastuzumab Figure 2b: Disease-free survival BMI group for treatment Arm B: Sequential trastuzumab Figure 2c: Disease-free survival BMI group for treatment Arm C: Concurrent trastuzumab

Figure 2

Figure 2a: Disease-free survival BMI group for treatment Arm A: No trastuzumab Figure 2b: Disease-free survival BMI group for treatment Arm B: Sequential trastuzumab Figure 2c: Disease-free survival BMI group for treatment Arm C: Concurrent trastuzumab

Figure 2

Figure 2a: Disease-free survival BMI group for treatment Arm A: No trastuzumab Figure 2b: Disease-free survival BMI group for treatment Arm B: Sequential trastuzumab Figure 2c: Disease-free survival BMI group for treatment Arm C: Concurrent trastuzumab